GSK has announced that current CEO, Emma Walmsley, will step down from her position in early 2026. She will be replaced by Luke Miels, the current Chief Strategy Officer. This change is aimed at introducing a new vision and direction of the company’s development, especially in the context of growing competition on the pharmaceutical market. Investors positively assessed this decision, which translated into an increase in the value of GSK shares.
